# Clinical features and treatment outcomes of acute-onset endophthalmitis caused by Staphylococcus lugdunensis: a case series

## TL;DR

This study examines eye infections caused by Staphylococcus lugdunensis and finds that treatment with vancomycin leads to good outcomes.

## Contribution

The study provides updated data on the effectiveness of vancomycin against S. lugdunensis in eye infections.

## Key findings

- All S. lugdunensis isolates were sensitive to vancomycin and moxifloxacin.
- Most patients achieved a visual acuity of 20/150 or better after treatment.
- Vancomycin remains a reliable empiric treatment for this type of eye infection.

## Abstract

To report a series of patients with acute-onset endophthalmitis caused by culture-proven Staphylococcus lugdunensis and to provide an update on the microbiologic susceptibility and clinical outcomes resulting from this organism.

This study included 6 eyes of 6 patients. The etiologies included cataract surgery (4), intravitreal injection (1), and posterior segment surgery (1). All isolates (100%) of S. lugdunensis demonstrated sensitivity to vancomycin with minimal inhibitory concentration (MIC) values ranging from ≤ 0.5 to 1 mcg/mL and to moxifloxacin with MIC values ranging from ≤ 0.25 to 1 mcg/mL. One of 6 isolates demonstrated intermediate resistance to gentamicin with a MIC value of 8 mcg/mL. Four of 6 patients underwent pars plana vitrectomy following initial treatment with intravitreal antibiotics, and 1 eye underwent vitrectomy as initial management. Best-corrected visual acuity at last follow-up examination was≥ 20/150 in 5/6 (83.3%) of cases and ≥ 20/40 in 3/6 (50%) of cases.

In this study, patients with acute-onset endophthalmitis caused by S. lugdunensis had relatively good outcomes, similar to a previous case series. Vancomycin continues to have consistent coverage against S. lugdunensis and remains an empiric therapeutic option for acute-onset endophthalmitis.